Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | PTAFR | P25105 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | EED | O75530 | 1/20 | 0.31 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.31 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.31 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13851469 | 0.82 | QDPR (0.46) | QDPRNOTUMPTAFRNAMPT | |
| SCHEMBL23561248 | 0.81 | QDPR (0.39) | QDPRNOTUMPTAFRRIPK1NAMPT | |
| SCHEMBL19226549 | 0.78 | QDPR (0.36) | QDPRNAMPTALDH1A1 | |
| SCHEMBL21936851 | 0.75 | NOTUM (0.39) | QDPRNOTUMPTAFRRIPK1HRH3 | |
| SCHEMBL20115300 | 0.74 | QDPR (0.36) | QDPRL3MBTL1MEN1KMT2A | |
| SCHEMBL13900834 | 0.74 | QDPR (0.45) | QDPRNOTUMPTAFRNAMPTHRH3 | |
| SCHEMBL20243870 | 0.72 | TDO2 (0.37) | EEDRBBP4SUZ12EZH2 | |
| SCHEMBL12139829 | 0.71 | BLM (0.39) | NAMPTMEN1KMT2AALDH1A1 | |
| SCHEMBL8261115 | 0.71 | QDPR (0.49) | QDPRNOTUMPTAFRNAMPTALDH1A1 | |
| SCHEMBL8386277 | 0.71 | QDPR (0.53) | QDPRNOTUMPTAFRNAMPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919912-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200131195-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2020-04-30 | — | — | US | disclosed |
| US-10464947-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2019-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131195-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | QDPR 4018/4885NOTUM 3538/4885PTAFR 3759/4885 |
| US-10464947-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | QDPR 4018/4885NOTUM 3538/4885PTAFR 3759/4885 |
| US-10919912-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | QDPR 4018/4885NOTUM 3538/4885PTAFR 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.